# Vudalimab

Source: https://onco.cc/drugs/vudalimab/  
OnCo record `vudalimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.

## Summary

Vudalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Xencor, Inc., in ovarian cancer, endometrial cancer, cervical cancer, prostate cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Bispecific antibody
- Mechanism: A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.

## Sources

- ClinicalTrials.gov: trials of Vudalimab: https://clinicaltrials.gov/search?intr=Vudalimab

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Xencor](https://onco.cc/companies/xencor/)
- trials: [A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies](https://onco.cc/trials/nct05032040/)

---
JSON: https://onco.cc/api/v1/entities/vudalimab.json